CG Oncology director granted 9,354 stock options

CG Oncology director Brian Guan-Chyun Liu received a grant of stock options for 9,354 shares of common stock.

Rhea-AI Filing Summary

CG Oncology director Brian Guan-Chyun Liu received a grant of stock options for 9,354 shares of common stock. These Director Stock Options give him the right to buy shares at an exercise price of $56.09 per share and expire on June 3, 2036.

The options vest over time: 1/12 of the total vests monthly after the June 4, 2026 grant date, as long as he continues serving the company. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date.

Insider Trade Summary

Grant/Award: 9,354 shares

Grant/Award 1 txn

Insider Liu Brian Guan-Chyun

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,354	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 9,354 contracts (Direct)

Footnotes (1)

1. F1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Options granted: 9,354 options Exercise price: $56.09 per share Expiration date: June 3, 2036 +2 more

5 metrics

Options granted 9,354 options Director Stock Option grant for common stock

Exercise price $56.09 per share Director Stock Option strike price

Expiration date June 3, 2036 Option expiration

Shares underlying options 9,354 shares Common stock underlying Director Stock Options

Vesting schedule 1/12 monthly Monthly vesting after June 4, 2026, subject to service

Key Terms

Director Stock Option, exercise price, expiration date, vesting, +1 more

5 terms

Director Stock Option financial

"Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "56.0900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CGON director Brian Guan-Chyun Liu report in this Form 4?

He reported receiving a grant of Director Stock Options for 9,354 shares. These options allow him to purchase CG Oncology common stock at $56.09 per share as part of his director compensation, rather than reflecting any open-market buying or selling activity.

How many CG Oncology (CGON) shares are covered by Liu’s new stock options?

The grant covers options on 9,354 shares of CG Oncology common stock. All 9,354 options are reported as held directly after the transaction, showing his full option position from this grant in the filing’s post-transaction holdings line.

What is the exercise price of Brian Liu’s CGON Director Stock Options?

The options have an exercise price of $56.09 per share. This means Liu can buy CG Oncology common stock at $56.09, regardless of future market prices, once the options have vested and before they expire in June 2036.

How do Brian Liu’s CGON stock options vest over time?

One-twelfth of the total options vest monthly after June 4, 2026, the grant date. Vesting continues as long as he remains in continuous service, with any remaining unvested portion vesting at the next annual stockholders’ meeting if it occurs within the first year.

When do Brian Liu’s CGON Director Stock Options expire?

The options expire on June 3, 2036, according to the filing. After that expiration date, any unexercised options will no longer be valid, so they must be exercised before then if he intends to purchase the underlying shares.

Was this CGON Form 4 a market purchase or sale of shares?

No. The Form 4 reports a grant of Director Stock Options, coded as an acquisition (A) for compensation. There was no open-market buying or selling of CG Oncology common stock in this transaction; it reflects equity-based compensation instead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Brian Guan-Chyun

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$56.09	06/04/2026		A		9,354		(1)	06/03/2036	Common Stock	9,354	$0	9,354	D

Explanation of Responses:

1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Brian Guan-Chyun Liu	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)